Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company with offices in Redwood City, California and Boston, Massachusetts, discovering and developing allogeneic "off-the-shelf" gamma delta T cell therapies engineered with chimeric antigen receptors (CARs) for autoimmune disease and cancer. Its lead candidate, prulacabtagene leucel (prula-cel), is an anti-CD20 gamma delta CAR T cell therapy in development for B cell-mediated autoimmune diseases, alongside ADI-212 for metastatic castration-resistant prostate cancer. Adicet publishes a corporate website covering its science platform, clinical pipeline, leadership and careers, plus a vendor-hosted investor relations portal. It operates no public developer program, API, SDK, or machine-readable interface of any kind; this profile records that absence rather than an API surface.
Adicet Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Cell Therapy, and Immunotherapy.
Adicet Bio’s developer surface includes support and 7 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/adicet-bio: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: adicet-bio
name: Adicet Bio
description: 'Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company with offices in Redwood City, California
and Boston, Massachusetts, discovering and developing allogeneic "off-the-shelf" gamma delta T cell therapies engineered
with chimeric antigen receptors (CARs) for autoimmune disease and cancer. Its lead candidate, prulacabtagene leucel (prula-cel),
is an anti-CD20 gamma delta CAR T cell therapy in development for B cell-mediated autoimmune diseases, alongside ADI-212
for metastatic castration-resistant prostate cancer. Adicet publishes a corporate website covering its science platform,
clinical pipeline, leadership and careers, plus a vendor-hosted investor relations portal. It operates no public developer
program, API, SDK, or machine-readable interface of any kind; this profile records that absence rather than an API surface.'
image: https://www.adicetbio.com/themes/default/images/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/adicet-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-07'
modified: '2026-09-07'
tags:
- Company
- Biotechnology
- Life Sciences
- Cell Therapy
- Immunotherapy
- Oncology
- Autoimmune
- Clinical Trials
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: LLMsTxt
url: llms/adicet-bio-llms.txt
- type: DomainSecurity
url: security/adicet-bio-domain-security.yml
- type: Website
url: https://www.adicetbio.com/
- type: About
url: https://www.adicetbio.com/about/
- type: Support
url: https://www.adicetbio.com/contact/
- type: TermsOfService
url: https://www.adicetbio.com/terms-of-use/
- type: PrivacyPolicy
url: https://www.adicetbio.com/privacy/
- type: Careers
url: https://www.adicetbio.com/careers/openings/
x-enrichment:
date: '2026-09-07'
status: minimal
artifacts_added: 3
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: Adicet Bio is a clinical-stage cell-therapy biotech — its products are investigational gamma delta CAR T cell therapies,
not software — and its entire public surface is a nine-page corporate marketing site plus a vendor-hosted investor relations
portal; every OpenAPI, Swagger, GraphQL, MCP, agent-card and /.well-known/ path probed on adicetbio.com, www.adicetbio.com
and investor.adicetbio.com returned 404, 301 or 403, and the site contains no developer, API, docs or integrations link
anywhere in its navigation.
evidence:
- url: https://www.adicetbio.com/openapi.json
status: 404
- url: https://www.adicetbio.com/.well-known/agent-card.json
status: 404
- url: https://www.adicetbio.com/llms.txt
status: 404
- url: https://www.adicetbio.com/graphql
status: 404
- url: https://www.adicetbio.com/
status: 200
checked: '2026-09-07'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.